Understanding Complex Product Characterization Analysis Session 2c
Exploring Complex Product Characterization Analysis Session 2c reveals several interesting facts. A presentation and panel assess analytical methods currently considered most useful and how to better develop these ...
Key Takeaways about Complex Product Characterization Analysis Session 2c
- Asif Rasheed from the Office of Pharmaceutical Quality discusses common issues and challenges for
- Rachel Dunn, PhD, Director of the Division of Pharmaceutical
- Presenters Cameron Smith, Deyi Zhang, and Xiaoming Xu answer audience questions. Learn more at ...
- Satish Sharan from CDER's Office of Generic Drugs discusses application of modeling and simulation in establishing appropriate ...
- FDA discusses additional topics in
Detailed Analysis of Complex Product Characterization Analysis Session 2c
A presentation and panel discuss new analytical methods that are promising for generic drug development, screening, and ... A presentation and panel discuss potential gaps in Yiwei Li from CDER's Office of Pharmaceutical Quality shares a case study, an introduction to Iron Colloid Drug
Bryan Newman, Denise Conti, Kimberly Witzmann, Tian Ma, Fang Yuan, and Bhagwant Rege respond to audience questions.
Stay tuned for more updates related to Complex Product Characterization Analysis Session 2c.